**Table S5-1.** Effect of MSC and S1P combination therapy on the expression change of TNF-α (\*\* *p*<0.01).

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| control | | | MSC\*\* | | | 0.5μMS1P+MSC\*\* | | |
| 1.000 | 1.000 | 1.000 | 0.334 | 0.160 | 0.232 | 0.122 | 0.036 | 0.1530 |

**Table S5-2.** Effect of MSC and S1P combination therapy on the expression change of S1P receptors 1, 2 and 3 (\*\* *p*<0.01).

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | control | | | MSC | | | 0.5μMS1P+MSC | | |
| S1PR1 | 1.000 | 1.000 | 1.000 | 0.864 | 0.430 | 0.495\*\* | 0.683 | 0.759 | 0.9740\*\* |
| S1PR2 | 1.000 | 1.000 | 1.000 | 0.224 | 0.073 | 0.128\*\* | 0.102 | 0.061 | 0.0625\*\* |
| S1PR3 | 1.000 | 1.000 | 1.000 | 0.141 | 0.053 | 0.086\*\* | 0.075 | 0.034 | 0.1760\*\* |

**Table S5-3.** Effect of MSC and S1P combination therapy on the expression change of sphingosine kinases 1 and 2 (\*\* *p*<0.01).

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | control | | | MSC | | | 0.5μMS1P+MSC | | |
| SphK1 | 1.000 | 1.000 | 1.000 | 0.502 | 0.332 | 0.403\*\* | 0.574 | 0.294 | 0.5510\*\* |
| SphK2 | 1.000 | 1.000 | 1.000 | 1.033 | 1.049 | 1.035 | 0.534 | 0.593 | 0.7870\*\* |